Paul R. Fonteyne - Net Worth and Insider Trading
Paul R. Fonteyne Net Worth
The estimated net worth of Paul R. Fonteyne is at least $281,534 dollars as of 2024-11-10. Paul R. Fonteyne is the Director of Apellis Pharmaceuticals Inc and owns about 5,000 shares of Apellis Pharmaceuticals Inc (APLS) stock worth over $150,100. Paul R. Fonteyne is the Director of Covetrus Inc and owns about 5,000 shares of Covetrus Inc (CVET) stock worth over $104,950. Paul R. Fonteyne is also the Director of Amylyx Pharmaceuticals Inc and owns about 3,947 shares of Amylyx Pharmaceuticals Inc (AMLX) stock worth over $26,484. Details can be seen in Paul R. Fonteyne's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul R. Fonteyne has not made any transactions after 2022-01-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Paul R. Fonteyne
Paul R. Fonteyne Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul R. Fonteyne owns 6 companies in total, including AMAG Pharmaceuticals Inc (AMAG) , Apellis Pharmaceuticals Inc (APLS) , and Amylyx Pharmaceuticals Inc (AMLX) among others .
Click here to see the complete history of Paul R. Fonteyne’s form 4 insider trades.
Insider Ownership Summary of Paul R. Fonteyne
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AMAG | AMAG Pharmaceuticals Inc | 2020-06-02 | director |
| APLS | Apellis Pharmaceuticals Inc | 2023-01-01 | director |
| AMLX | Amylyx Pharmaceuticals Inc | 2022-01-06 | director |
 | | 2018-01-25 | director |
| | 2021-08-10 | director |
| | 2022-01-13 | director |
Paul R. Fonteyne Latest Holdings Summary
Paul R. Fonteyne currently owns a total of 3 stocks. Among these stocks, Paul R. Fonteyne owns 5,000 shares of Apellis Pharmaceuticals Inc (APLS) as of May 8, 2020, with a value of $150,100 and a weighting of 53.31%. Paul R. Fonteyne owns 5,000 shares of Covetrus Inc (CVET) as of August 10, 2021, with a value of $104,950 and a weighting of 37.28%. Paul R. Fonteyne also owns 3,947 shares of Amylyx Pharmaceuticals Inc (AMLX) as of January 6, 2022, with a value of $26,484 and a weighting of 9.41%.
Latest Holdings of Paul R. Fonteyne
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals Inc | 2020-05-08 | 5,000 | 30.02 | 150,100 |
| CVET | Covetrus Inc | 2021-08-10 | 5,000 | 20.99 | 104,950 |
| AMLX | Amylyx Pharmaceuticals Inc | 2022-01-06 | 3,947 | 6.71 | 26,484 |
Holding Weightings of Paul R. Fonteyne
Paul R. Fonteyne Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul R. Fonteyne has made a total of 1 transactions in Apellis Pharmaceuticals Inc (APLS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Apellis Pharmaceuticals Inc is the acquisition of 5,000 shares on May 8, 2020, which cost Paul R. Fonteyne around $159,050.
According to the SEC Form 4 filings, Paul R. Fonteyne has made a total of 1 transactions in Covetrus Inc (CVET) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Covetrus Inc is the acquisition of 5,000 shares on August 10, 2021, which cost Paul R. Fonteyne around $116,200.
According to the SEC Form 4 filings, Paul R. Fonteyne has made a total of 1 transactions in Amylyx Pharmaceuticals Inc (AMLX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Amylyx Pharmaceuticals Inc is the acquisition of 3,947 shares on January 6, 2022, which cost Paul R. Fonteyne around $74,993.
Insider Trading History of Paul R. Fonteyne
- 1
Paul R. Fonteyne Trading Performance
GuruFocus tracks the stock performance after each of Paul R. Fonteyne's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul R. Fonteyne is -18.35%. GuruFocus also compares Paul R. Fonteyne's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul R. Fonteyne within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul R. Fonteyne's insider trading performs compared to the benchmark.
Performance of Paul R. Fonteyne
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -3.54 | | | | | |
| Relative Return to S&P 500(%) | -8.95 | | | | | |
Paul R. Fonteyne Ownership Network
Ownership Network List of Paul R. Fonteyne
Ownership Network Relation of Paul R. Fonteyne
Paul R. Fonteyne Owned Company Details
What does AMAG Pharmaceuticals Inc do?
Who are the key executives at AMAG Pharmaceuticals Inc?
Paul R. Fonteyne is the director of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Lp , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .
AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.
AMAG Pharmaceuticals Inc Insider Transactions
Paul R. Fonteyne Mailing Address
Above is the net worth, insider trading, and ownership report for Paul R. Fonteyne. You might contact Paul R. Fonteyne via mailing address: C/o Restorbio, Inc., 501 Boylston Street Suite 6102, Boston Ma 02116.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
